Agendia Gets FDA Clearance for MammaPrint on Agilent Systems | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia has received another clearance for the firm's MammaPrint breast cancer recurrence assay.

The new clearance is for running the test on two additional Agilent microarray scanners and two Agilent Bioanalyzers. Agendia said the additional clearance will expand laboratory capacity to handle the increasing number of MammaPrint, TargetPrint, and BluePrint test results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.